PMID- 37937574
OWN - NLM
STAT- Publisher
LR  - 20231108
IS  - 2212-3970 (Electronic)
IS  - 1574-8928 (Linking)
DP  - 2023 Nov 3
TI  - Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case 
      Report and Brief Review.
LID - 10.2174/0115748928247369231024112003 [doi]
AB  - INTRODUCTION: Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B 
      lymphocyte proliferative disease. Generally, SMZL is accompanied by circulating 
      atypical villous lymphocytes, known as SMZL with villous lymphocytes. Rituximab 
      is a chimeric monoclonal antibody to CD20; recent but limited studies have 
      confirmed its effectiveness in treating SMZL. Given the low incidence and 
      selection of treatment, statistical comparisons of rituximab monotherapy with 
      other available treatment options with the full range of data from previous 
      clinical studies remain sparse. Here, we report a case of SMZL with villous 
      lymphocytes treated by rituximab monotherapy, which is especially infrequently 
      reported. CASE REPORT: A 63-year-old Chinese female was presented to the hospital 
      with complaints of splenomegaly and pain in the spleen area. Immunohistochemistry 
      analysis was positive for IGH, IGK, and IGL clonal rearrangement. Villous 
      lymphocytes were found in peripheral blood and bone marrow, along with further 
      immunotyping results. The case was considered as SMZL with villous lymphocytes. 
      Based on the SMZLSG prognosis assessment, we applied rituximab monotherapy. After 
      eight cycles of rituximab treatment, the patient's condition improved markedly, 
      with blood constituent and size of the spleen returning to normal levels, 
      achieving complete response, with no significant side effect observed. 
      DISCUSSION: The patient provides a typical SMZL with villous lymphocytes case 
      treated with rituximab monotherapy. Currently, the main treatment options include 
      splenectomy and rituximab. After synthesizing a series of current views, we put 
      forward our opinion about the selection of therapy for SMZL patients in order to 
      gain maximum benefits for patients in need of treatment. CONCLUSION: Our analysis 
      found no statistically significant difference between rituximab monotherapy and 
      rituximab combined with chemotherapy, while rituximab treatments resulted in 
      better therapeutic effects than chemotherapy. Rituximab monotherapy has favorable 
      therapeutic effects and minor adverse effects (AEs) in treating SMZL.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Guan, Rong-Yan
AU  - Guan RY
AD  - Department of Hematology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, 
      China.
FAU - Tang, Xing-Ru
AU  - Tang XR
AUID- ORCID: 0000-0002-9837-9586
AD  - Department of Clinical Medicine, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Huang, Zou-Fang
AU  - Huang ZF
AD  - Ganzhou Key Laboratory of Hematology, Department of Hematology, The First 
      Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, 
      China.
FAU - Du, Jun
AU  - Du J
AD  - Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Fu, Xue-Hang
AU  - Fu XH
AD  - Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Lu, Guang
AU  - Lu G
AD  - Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong, 
      China.
FAU - Mou, Wei-Wei
AU  - Mou WW
AD  - Department of Pediatrics, Shengli Oilfield Central Hospital, Shandong, Dongying, 
      Shandong, China.
LA  - eng
PT  - Case Reports
DEP - 20231103
PL  - United Arab Emirates
TA  - Recent Pat Anticancer Drug Discov
JT  - Recent patents on anti-cancer drug discovery
JID - 101266081
SB  - IM
OTO - NOTNLM
OT  - Case reporSplenic marginal zone lymphoma
OT  - Case report
OT  - Monotherapy
OT  - Rituximab
OT  - Splenic marginal zone lymphoma
EDAT- 2023/11/08 12:42
MHDA- 2023/11/08 12:42
CRDT- 2023/11/08 06:40
PHST- 2023/03/12 00:00 [received]
PHST- 2023/08/16 00:00 [revised]
PHST- 2023/08/29 00:00 [accepted]
PHST- 2023/11/08 12:42 [medline]
PHST- 2023/11/08 12:42 [pubmed]
PHST- 2023/11/08 06:40 [entrez]
AID - PRA-EPUB-135867 [pii]
AID - 10.2174/0115748928247369231024112003 [doi]
PST - aheadofprint
SO  - Recent Pat Anticancer Drug Discov. 2023 Nov 3. doi: 
      10.2174/0115748928247369231024112003.